Drug intelligence / Profile preview

Asp-GTC-3'tDR

Development stage
Preclinical
Lead developer
Massachusetts General Hospital
Modality
Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Parenteral
01

Overview

Asp-GTC-3'tDR is an ischemia-induced tRNA-derived small RNA (tsRNA or tDR) derived from the 3' end of tRNA-Asp-GTC. It serves as an endogenous regulatory molecule that mitigates cardiac fibrosis and heart failure progression. Mechanistically, Asp-GTC-3'tDR enhances autophagic flux and suppresses TGFβ signaling and extracellular matrix assembly pathways. It interacts with ribosomal proteins and stalled ribosomes to promote the formation of stress granules, which are subsequently targeted for degradation via the autophagy pathway. Therapeutic delivery of Asp-GTC-3'tDR mimics using polymer nanoparticles has demonstrated the ability to alleviate adverse cardiac remodeling and improve cardiac function in preclinical models of myocardial infarction.

Other names
Asp-GTC-3' tRNA-derived small RNAAsp-GTC-3' tsRNAtRNA-Asp-GTC-derived small RNA
02

Targets

PUS7 (Pseudouridine synthase 7)

Beyond the preview

Go deeper on Asp-GTC-3'tDR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asp-GTC-3'tDR.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call